Business Wire

New Optimum® Class VI Dispensing Components Provide Assurance to Medical Manufactures

15.9.2020 17:02:00 EEST | Business Wire | Press release

Share

Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, introduces Optimum® Class VI fluid dispensing components made from 100% virgin resin that is Class VI certified by the U.S. Pharmacopeial Convention (USP).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005026/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Optimum Class VI dispensing components are manufactured from USP Class VI resin, making these biocompatible components ideal for medical device manufacturing. (Photo: Business Wire)

“We wanted to make it easier for medical manufacturers to provide the traceability required to meet strict regulatory standards,” said Felicitas Stuebing, global product line specialist at Nordson EFD. “Meeting the most stringent USP Class designation is not only a testament to the quality of our components, it provides peace of mind that our components are safe to use in medical manufacturing processes.”

New Optimum Class VI dispensing components include 3cc, 5cc, 10cc, 30cc, and 55cc syringe barrels and pistons, in addition to end caps and tip caps. These biocompatible components do not have a colorant, making them easier for engineers to document for regulatory approvals.

In addition, these first-to-market medical-grade dispensing components feature the same highly-engineered design as standard Optimum components. The Class VI syringe barrels feature ZeroDraft™ walls with consistent internal diameters that maintain an airtight seal with Class VI pistons to provide accurate, repeatable fluid deposits used in bonding, coating, and other medical assembly processes.

These components also pass the same rigorous quality standards Nordson EFD maintains to ensure a consistent product that provides consistent performance.

Ethylene oxide (ETO), autoclave, and gamma sterilization methods were tested to determine the impact on Optimum Class VI dispensing components. Those results can be found in the product data sheet, though Nordson EFD states that all customers must to do their own testing to validate their processes.

For more information, visit Nordson EFD on the web at nordsonefd.com/ClassVI, linkedin.com/company/nordson-efd, email at info@nordsonefd.com, or call +1 401.431.7000 or 800.556.3484.

About Nordson EFD

Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.

About Nordson Corporation

Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nordson EFD

Global
Natalie Tomasso
Marketing Communications Specialist
+1-401-431-7173 (USA); natalie.tomasso@nordsonefd.com

Europe
+44 (0) 1582 666334; infoefd.europe@nordsonefd.com

China
+86 (21) 3866 9006; china@nordsonefd.com

Japan
+81 (03) 5762 2760; japan@nordsonefd.com

Korea
+82 (31) 7368321; korea@nordsonefd.com

SEAsia
+65 6796 9522; sin-mal@nordsonefd.com

India
+91 80 4021 3600; india@nordsonefd.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release

ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol

MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 16:36:00 EEST | Press release

MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also incl

Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 16:00:00 EEST | Press release

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction Transactions Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million. Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million. “Our year-to-date share repurchases

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye